Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN).
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 609 322 1602 |
| Website | gracetx.com |
Stock Details
| Ticker Symbol | GRCE |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| CUSIP Number | 00439U104 |
| ISIN Number | US00439U1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Consultant |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 28, 2026 | DEF 14A | Other definitive proxy statements |
| Jul 28, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 10-K | Annual Report |
| Jun 5, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |